At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Ixekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
In Brief
A Phase 2 clinical trial evaluating Ixekizumab for Pityriasis Rubra Pilaris. Completed, enrolled 12 participants across 1 site.
Detailed Summary
15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPityriasis Rubra Pilaris
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionOct 2019
Study CompletionJan 2020
TodayJul 2026
First PostedApr 3, 2018
Enrollment StartMay 23, 2018
Primary CompletionOct 14, 2019
Study CompletionJan 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.2 years ago
Interventions
Ixekizumabdrug
Treatment at the FDA-approved psoriasis dosing